Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40396
Title: Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis
Authors: Valgimigli, M
Smits, PC
Frigoli, E
Bongiovanni, D
Tijssen, J
Hovasse, T
Mafragi, A
Ruifrok, WT
Karageorgiev, D
Aminian, A
Garducci, S
Merkely, B
Routledge, H
Ando, K
Fernandez, JFD
Cuisset, T
Malik, FTN
Halabi, M
Belle, L
Din, J
Beygui, F
Abhyankar, A
Reczuch, K
Pedrazzini, G
Heg, D
VRANCKX, Pascal 
Issue Date: 2022
Publisher: OXFORD UNIV PRESS
Source: EUROPEAN HEART JOURNAL, 43 (33) , p. 3100 -3114
Abstract: Aim To assess the effects of 1- or >= 3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS). Methods and results In the MASTER DAPT trial, 3383 patients underwent non-complex (abbreviated DAPT, n = 1707; standard DAPT, n = 1676) and 1196 complex (abbreviated DAPT, n = 588; standard DAPT, n = 608) PCI. Co-primary outcomes at 335 days were net adverse clinical events [NACE; composite of all-cause death, myocardial infarction, stroke, and bleeding academic research consortium (BARC) 3 or 5 bleeding events]; major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial infarction, and stroke); and Types 2, 3, or 5 BARC bleeding. Net adverse clinical events and MACCE did not differ with abbreviated vs. standard DAPT among patients with complex [hazard ratio (HR): 1.03, 95% confidence interval (CI): 0.69-1.52, and HR: 1.24, 95% CI: 0.79-1.92, respectively] and non-complex PCI (HR: 0.90, 95% CI: 0.71-1.15, and HR: 0.91, 95% CI: 0.69-1.21; P-interaction = 0.60 and 0.26, respectively). BARC 2, 3, or 5 was reduced with abbreviated DAPT in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42-0.98, and HR: 0.70; 95% CI: 0.55-0.89; P-interaction = 0.72). Among the 2816 patients with complex PCI and/or ACS, NACE and MACCE did not differ and BARC 2, 3, or 5 was lower with abbreviated DAPT. Conclusion In HBR patients free from recurrent ischaemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI or patient complexity.
Keywords: Percutaneous coronary intervention;High bleeding risk;Dual antiplatelet therapy;Complex intervention
Document URI: http://hdl.handle.net/1942/40396
ISSN: 0195-668X
e-ISSN: 1522-9645
DOI: 10.1093/eurheartj/ehac284
ISI #: 000815258900001
Category: A1
Type: Journal Contribution
Validations: ecoom 2023
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
ehac284.pdfPublished version1.26 MBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.